Overview

    BPMC (Common Stock) $46.58 Stock is Up 0.58 (1.26%)
    Volume578,881
    04/28/17 4:00 p.m. ET
    Data provided by Nasdaq. Minimum 15
    minutes delay
    Refresh quote

    Corporate Profile

    Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Read More

    Upcoming Events

    Q1 2017 Blueprint Medicines Corp Earnings Conference Call
    Wednesday, May 3, 2017 8:30 a.m. ET

    View More

    Presentation

    Blueprint Medicines – Investor Presentation (April 2017)


    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet